Sunday 18 October 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.8%, free cash flow grew 43.2% and total debt rose 5.65%, each against the same quarter a year earlier.
1.69
0.02
+1.20%
Follow ABOS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 6.20 | 3.02 | 1.81 | 1.69 | 0.86 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 26.98 | 10.97 | 11.31 | 5.09 | 2.46 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 7 | 17 | 40 | 52 | 61 | 61 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 2 | 1 | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (8) | (7) | (101) | (43) | (52) | (102) | (121) | |||||
| EBT margin, % | — | — | — | (465.94) | (510.10) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (8) | (7) | (101) | (43) | (52) | (102) | (121) | |||||
| Depreciation | — | — | — | — | — | 0 | 1 | (3) | (5) | (1) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 3.94 | 3.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (18.35) | (17.48) | (5.02) | (1.06) | (1.08) | (1.71) | (2.00) | |||||
| Cash flow | — | — | — | (15.83) | (17.78) | (0.90) | (0.87) | (0.89) | (1.44) | (1.91) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (15.83) | (17.78) | (0.90) | (0.87) | (0.89) | (1.44) | (1.91) | |||||
| Book value | — | — | — | (26.51) | (44.37) | 11.23 | 4.65 | 5.49 | 3.03 | 1.16 | |||||
| Shares, m | — | — | — | 0 | 0 | 20 | 41 | 49 | 60 | 61 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | — | — | — | — | ||||
| P/S | — | — | — | 6.05 | 6.05 | — | — | — | — | — | |||||
| P/B | — | — | — | 0.00 | 0.00 | — | — | — | — | — | |||||
| EV/Sales | — | — | — | (41.87) | (41.87) | — | — | — | — | — | |||||
| EV/FCF | — | — | — | 5.58 | 5.58 | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (7) | (7) | (18) | (35) | (43) | (86) | (116) | ||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (7) | (7) | (18) | (35) | (43) | (86) | (116) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 6 | 43 | 194 | 173 | 234 | 151 | 92 | ||||
| Total debt | — | — | — | — | — | — | 0 | 30 | 29 | 31 | |||||
| Net debt | — | — | — | (7) | (44) | (194) | (177) | (214) | (142) | (86) | |||||
| Shareholders’ equity | — | — | — | (11) | (19) | 225 | 189 | 267 | 182 | 70 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (209.94) | (28.31) | (73.23) | (20.08) | (20.67) | (37.27) | (67.07) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (39.55) | (250.76) | (71.63) | (179.60) | 0.00 | |||||
| ROE | — | — | — | 51.22 | 48.82 | (97.40) | (20.71) | (22.98) | (45.60) | (96.20) | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Dec 2020
Charts ten years each
Acumen Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics, Inc. | $126.9M | — (loss-making) | — (loss-making) | −39.13% (below 0%: shrinking) | n/m | +24.80% (above 0%: growing) | 100.00% | (833.87%) | Compare |
| HUMA Humacyte, Inc. | $122.1M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | Compare |
| OTLK Outlook Therapeutics, Inc. | $121.7M | — (loss-making) | — (loss-making) | −99.42% (below 0%: shrinking) | n/m | −76.54% (below 0%: shrinking) | (95.40%) | (124,255.17%) | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $120.8M | — (loss-making) | — | — | n/m | +43.23% (above 0%: growing) | 0.00% | 0.00% | |
| SPRB Spruce Biosciences, Inc. | $119.2M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $117.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| HURA TuHURA Biosciences, Inc. | $116.6M | — (loss-making) | — | — | n/m | −70.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NERV Minerva Neurosciences, Inc | $115.6M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $114.9M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| Median of peers | $118.3M | — | — | −39.13% | — | −73.50% | 19.35% | (500.83%) |
Acumen Pharmaceuticals, Inc. (ABOS) key facts
- Concern: Acumen Pharmaceuticals, Inc. reported a net loss of $121.3 million, or a loss of $2.00 per share, for fiscal 2025.
- Acumen Pharmaceuticals, Inc. (ABOS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ABOS traded at $1.69, a market capitalization of $120.8 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 85.0× sales.
- Return on equity was −96.2% and debt-to-equity 0.55.